- Home
- Member Resources
- Articles
- Precision Medicine
-
Solid organ transplantation is a critical treatment for end-stage disease, but post-transplant complications, such as acute rejection, remain a significant challenge.
-
Pathologists Jie-Fu Chen, MD, FCAP, and JinJuan Yao, MD, PhD, FCAP, highlight how molecular features, especially recurrent genomic alterations and mutational signatures, can suggest tumor type or site of origin and, in some cases, change the categorization of actionable targets for therapy.
-
For pathologists, ensuring analytically- and clinically-validated identification of MET alterations is of high importance in biomarker-driven diagnostics.
-
This article reviews the major updates in the diagnosis and classification of myelodysplastic syndromes (MDS) introduced by the WHO 5th edition and the International Consensus Classification (ICC). It compares these new frameworks with the 2017 WHO revised 4th edition, highlights key differences, and explores the implications for pathology practice, including molecular diagnostics and prognostic stratification.
-
Tissue provenance is the concept of assuring that tissue, whether in a container, on a slide or a swab, or in an instrument, is from the original source and authentic.
-
Explore how exosomes are advancing liquid biopsy technology, offering new possibilities for cancer diagnostics, monitoring, and personalized treatment strategies.
-
Immunohistochemical (IHC) markers can serve as surrogates for molecular genetic events, providing a practical tool for early and accurate diagnosis. These markers are particularly useful in soft tissue tumor pathology, where both benign and malignant neoplasms often have defining genetic events that result in protein overexpression or loss.
-
Explore the intricate relationship between Clonal Hematopoiesis of Indeterminate Potential (CHIP), inflammation, and cardiovascular disease. Learn about the genetic mutations involved, factors affecting CHIP, and potential therapeutic strategies to mitigate associated risks.
-
While allogenic cellular therapies (ACTs) offer promising off-the-shelf treatment options, addressing challenges in their development and implementation is essential for improving their safety, efficacy, and accessibility to a broader patient population.
-
Genetic and molecular testing are revolutionizing the diagnosis and treatment of salivary gland neoplasms, aiding in tumor classification, prognostication, and targeted therapy selection. This article explores key diagnostic biomarkers, emerging therapeutic targets, and the challenges of molecular testing, highlighting its growing role in precision oncology for these rare and heterogeneous tumors.
-
While once a distant possibility, the advancement of DNA methylation techniques is now bringing the potential for a pan-cancer DNA methylation classifiers closer to realization.
-
The goal of personalized healthcare (PHC) is to customize treatment to the individual characteristics of each patient, maximizing efficacy and minimizing adverse effects.
-
KRAS is the most common oncogenic driver gene in human cancers, with the highest mutation frequency in pancreatic adenocarcinoma, followed by colorectal adenocarcinoma (CRC), cholangiocarcinoma, and non-small cell lung cancer (NSCLC).
-
Estrogen receptor 1 (ESR1) mutations have emerged as a critical player in the progression and treatment resistance of breast cancer, particularly in metastatic hormone receptor-positive cases. These mutations are associated with resistance to endocrine therapy, the backbone of treatment for this type of cancer.
-
The absence of BCL2 expression in cases of follicular lymphoma (FL) presents a diagnostic challenge—one that must be solved to determine optimal prognosis and treatment.
-
This article examines the clinical importance of HRD status for patients with ovarian, breast, pancreas, and prostate cancers, as well as methodologies for measurement.
-
The CAP created this aid for pathologists on the processing and reporting of pregnancy tissues/products of conception (POC) specimens. This aid conveys general guidance on the issues that pathologists may face but does not convey legal advice.
-
Recent advances and innovations in microscopic imaging technology are demonstrating the potential to significantly enhance the current clinical practice of diagnostic pathology.
-
The field of immuno-oncology (IO) continues to expand and evolve, delivering unprecedented clinical benefit to patients across a growing number of tumor types. However, IO therapies are not effective in all patients and can be associated with autoimmune side effects, which can be severe.